Cargando…
Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients
Background: Adjuvant endocrine therapy (AET) reduces breast cancer recurrence and mortality of women with hormone-receptor-positive tumors, but poor adherence remains a significant problem. The aim of this study was to analyze AET side effects and their impact on adherence to treatment. Methods: A t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955792/ https://www.ncbi.nlm.nih.gov/pubmed/36826073 http://dx.doi.org/10.3390/curroncol30020112 |
_version_ | 1784894433967210496 |
---|---|
author | Rosso, Roberta D’Alonzo, Marta Bounous, Valentina Elisabetta Actis, Silvia Cipullo, Isabella Salerno, Elena Biglia, Nicoletta |
author_facet | Rosso, Roberta D’Alonzo, Marta Bounous, Valentina Elisabetta Actis, Silvia Cipullo, Isabella Salerno, Elena Biglia, Nicoletta |
author_sort | Rosso, Roberta |
collection | PubMed |
description | Background: Adjuvant endocrine therapy (AET) reduces breast cancer recurrence and mortality of women with hormone-receptor-positive tumors, but poor adherence remains a significant problem. The aim of this study was to analyze AET side effects and their impact on adherence to treatment. Methods: A total of 373 breast cancer patients treated with AET filled out a specific questionnaire during their follow up visits at the Breast Unit of our Centre. Results: Side effects were reported by 81% of patients, 84% of those taking tamoxifen and 80% of those taking aromatase inhibitors (AIs). The most common side effect in the tamoxifen group was hot flashes (55.6%), while in the AI group it was arthralgia (60.6%). The addition of GnRH agonists to both tamoxifen and AI significantly worsened all menopausal symptoms. Overall, 12% of patients definitively discontinued AET due to side effects, 6.4% during the first 5 years and 24% during extended therapy. Patients who had previously received chemotherapy or radiotherapy reported a significantly lower discontinuation rate. Conclusions: AET side effects represent a significant problem in breast cancer survivors leading to irregular assumption and discontinuation of therapy. Adherence to AET may be improved by trustful patient–physician communication and a good-quality care network. |
format | Online Article Text |
id | pubmed-9955792 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99557922023-02-25 Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients Rosso, Roberta D’Alonzo, Marta Bounous, Valentina Elisabetta Actis, Silvia Cipullo, Isabella Salerno, Elena Biglia, Nicoletta Curr Oncol Article Background: Adjuvant endocrine therapy (AET) reduces breast cancer recurrence and mortality of women with hormone-receptor-positive tumors, but poor adherence remains a significant problem. The aim of this study was to analyze AET side effects and their impact on adherence to treatment. Methods: A total of 373 breast cancer patients treated with AET filled out a specific questionnaire during their follow up visits at the Breast Unit of our Centre. Results: Side effects were reported by 81% of patients, 84% of those taking tamoxifen and 80% of those taking aromatase inhibitors (AIs). The most common side effect in the tamoxifen group was hot flashes (55.6%), while in the AI group it was arthralgia (60.6%). The addition of GnRH agonists to both tamoxifen and AI significantly worsened all menopausal symptoms. Overall, 12% of patients definitively discontinued AET due to side effects, 6.4% during the first 5 years and 24% during extended therapy. Patients who had previously received chemotherapy or radiotherapy reported a significantly lower discontinuation rate. Conclusions: AET side effects represent a significant problem in breast cancer survivors leading to irregular assumption and discontinuation of therapy. Adherence to AET may be improved by trustful patient–physician communication and a good-quality care network. MDPI 2023-01-21 /pmc/articles/PMC9955792/ /pubmed/36826073 http://dx.doi.org/10.3390/curroncol30020112 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rosso, Roberta D’Alonzo, Marta Bounous, Valentina Elisabetta Actis, Silvia Cipullo, Isabella Salerno, Elena Biglia, Nicoletta Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients |
title | Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients |
title_full | Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients |
title_fullStr | Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients |
title_full_unstemmed | Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients |
title_short | Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients |
title_sort | adherence to adjuvant endocrine therapy in breast cancer patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955792/ https://www.ncbi.nlm.nih.gov/pubmed/36826073 http://dx.doi.org/10.3390/curroncol30020112 |
work_keys_str_mv | AT rossoroberta adherencetoadjuvantendocrinetherapyinbreastcancerpatients AT dalonzomarta adherencetoadjuvantendocrinetherapyinbreastcancerpatients AT bounousvalentinaelisabetta adherencetoadjuvantendocrinetherapyinbreastcancerpatients AT actissilvia adherencetoadjuvantendocrinetherapyinbreastcancerpatients AT cipulloisabella adherencetoadjuvantendocrinetherapyinbreastcancerpatients AT salernoelena adherencetoadjuvantendocrinetherapyinbreastcancerpatients AT biglianicoletta adherencetoadjuvantendocrinetherapyinbreastcancerpatients |